« Return to News | Awards & Advancement

RxAlly names Tom O'Grady to leadership team

Tuesday, July 17, 2012 12:12 PM

RxAlly, a first-of-its-kind alliance of more than 22,000 pharmacies nationwide, has named Tom O'Grady to its leadership team.  As general counsel and executive vice president of corporate development, O’Grady brings more than 30 years of corporate and transactional law experience. He will be structuring business relationships between RxAlly and the companies and businesses it will be working with as it continues to align pharmacies and pharmacists, the patients they serve and the payer community.

O'Grady joins RxAlly from McGuireWoods, where he focused on transactional law for health care and other technology-enabled companies for 26 years. Previously, he practiced in South Africa, where he became a partner in Bowman Gilfillan, one of South Africa's largest law firms. He spent a year at Wall Street law firm Shearman & Sterling.

RxAlly is a performance network of more than 22,000 member pharmacies nationwide, united to help patients achieve better health while reducing costs. RxAlly aims to improve health through personalized pharmacist care, clinical research and evidence-based clinical practices, and an interoperable technology platform.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.